02:09:24 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-10 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-17 Årsstämma 2023
2023-05-05 Kvartalsrapport 2023-Q1
2023-02-24 Bokslutskommuniké 2022
2022-11-29 Extra Bolagsstämma 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning ALZCUR 0.00 SEK
2022-05-17 Årsstämma 2022
2022-05-05 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-11-10 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-18 Ordinarie utdelning ALZCUR 0.00 SEK
2021-05-17 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-25 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning ALZCUR 0.00 SEK
2020-05-20 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-15 Kvartalsrapport 2019-Q3
2019-08-31 Kvartalsrapport 2019-Q2
2019-05-23 Ordinarie utdelning ALZCUR 0.00 SEK
2019-05-22 Årsstämma 2019
2019-05-01 Kvartalsrapport 2019-Q1
2019-02-28 Bokslutskommuniké 2018

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
AlzeCure Pharma är ett läkemedelsbolag. Bolaget är inriktade mot forskning och utveckling av läkemedel som används för diverse hjärnsjukdomar, med störst fokus mot Alzheimers sjukdom. Teknologin och forskningen utgår ifrån egen läkemedelsplattform, där bolaget utvecklar olika symptomlindrande läkemedelskandidater. Huvudkontoret ligger i Huddinge.
2022-10-18 08:30:00

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on NeuroRestore ACD856 and its potential disease-modifying properties has been accepted for presentation at the annual Alzheimer's conference CTAD, Clinical Trials in Alzheimer's Disease, which this year is being held in San Francisco, November 29 - December 2.

The abstract, titled Preclinical characterization of ACD856, a cognitive enhancer in clinical development for the treatment of cognitive dysfunction in Alzheimer’s disease, demonstrates increased plasticity, neuroprotection and a possible disease modifying effect, will be presented at the international Alzheimer conference CTAD 2022 by Dr. Johan Sandin, CSO på AlzeCure. The other co-authors are Dr. Cristina Parrado-Fernández, Dr. Nather Madjid, Dr. Maria Backlund, Sanja Juric, Dr. Märta Dahlström, Dr. Gunnar Nordvall, Director of Medicinal Chemistry at AlzeCure, and Dr. Pontus Forsell, Head of Discovery & Research at AlzeCure.

The presentation contains preclinical results showing that ACD856, the leading drug candidate within the NeuroRestore platform, exhibits disease-modifying properties with both restorative and protective properties on nerve cells. The substance also has positive long-term effects after repeated administration, which indicates an enhanced plasticity in relevant neuronal pathways.

“Our results show that ACD856 has several positive effects on nerve cell function, both to protect neurons from damage but also to restore their function, which is of significant importance in neurodegenerative diseases characterized specifically by dysfunction and loss of nerve cells,” said Pontus Forsell, Head of Discovery & Research at AlzeCure Pharma.

“These new data further strengthen the potential disease-modifying effect of NeuroRestore ACD856, in addition to the memory-enhancing effect we previously observed in several preclinical models. The substance, which is now in the clinical phase, has so far shown very good clinical results, and these data further strengthen the external interest in the project," said Martin Jönsson, CEO of AlzeCure Pharma.

The abstract and poster will be available on AlzeCure's website after the presentation (https://www.alzecurepharma.se/en/presentations-and-interviews/).